

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

**POLL RESULT OF THE EXTRAORDINARY
GENERAL MEETING HELD ON 9 JULY 2026**

References are made to the circular (the “**Circular**”) and the notice of extraordinary general meeting (the “**EGM**”) of Fusen Pharmaceutical Company Limited (the “**Company**”), both dated 23 June 2026. Capitalised terms used in this announcement shall have the same meaning as those defined in the Circular unless otherwise defined herein.

The Board is pleased to announce that the resolution proposed at the EGM held at Units 5906–5912, 59th Floor, The Center, 99 Queen’s Road Central, Hong Kong on Thursday, 9 July 2026 at 2:00 p.m. was duly passed by the Shareholders by way of poll.

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

The poll result is as follows:

Ordinary Resolution	Number of Votes (%)		Total number of votes cast
	For	Against	
“THAT: (1) the entering into and the performance of the capital increase agreement (the “Capital Increase Agreement”) dated 18 June 2026 among Nanyang Hengsheng Enterprise Management Services Limited* (南陽衡盛企業管理服務有限公司), Wealth Depot (Hong Kong) Limited, Nanyang Industrial Investment Health Industry Group Co., Ltd.* (南陽產投健康產業集團有限公司) (“Nanyang Industrial Investment”), Henan Xisheng Industrial Development Co., Ltd.* (河南淅勝產業發展有限責任公司) (“Henan Xisheng”, together with Nanyang Industrial Investment, the “Investors”) and Henan Fusen Pharmaceutical Company Limited* (河南福森藥業有限公司) (the “Target Company”), in relation to the subscription of the newly increased registered capital of the Target Company by the Investors with an aggregate amount of RMB300 million in accordance with the Capital Increase Agreement (the “Capital Increase”), and the transactions contemplated thereunder (including the Capital Increase) be and are hereby approved, confirmed and ratified; and (2) any one or more of the directors of the Company be and are hereby authorised to do all such further acts and things, negotiate, approve, agree, sign, initial, ratify and/or execute such further documents which in their opinion may be necessary or desirable and take all steps which in their opinion may be necessary, desirable or expedient.”	334,883,100 (100%)	0 (0%)	334,883,100 (100%)

Notes:

- (a) As more than 50% of the votes were cast in favour of the above resolution, the resolution was duly passed as an ordinary resolution of the Company.
- (b) As at the date of the EGM, the total number of Shares in issue was 739,301,000 Shares.
- (c) The total number of issued Shares entitling the holder to attend and vote on the resolution at the EGM was 739,301,000 Shares.
- (d) As at the date of the EGM, there were no (i) treasury shares (as defined under the Listing Rules) held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury shares have been exercised at the EGM; and (ii) repurchased Shares which are pending cancellation and should therefore be excluded from the total number of issued Shares for the purpose of the EGM.
- (e) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Listing Rules, and none of the Shareholders has stated an intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.
- (f) No Shareholder was required under the Listing Rules to abstain from voting on the resolution at the EGM.
- (g) Shareholders holding an aggregate of 334,883,100 Shares, representing approximately 45.2973% of the total number of issued Shares, attended and voted at the EGM either in person or by proxy.
- (h) The Company's branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.
- (i) All Directors had attended the EGM.
- (j) All percentages are rounded to four decimal places.

By Order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 9 July 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Yu Ho Ming, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.